# Director, CMC – Small Molecule Chemistry at Pathos

- Company: Pathos
- What the company does: Drug development shouldn’t be guesswork, not when patients are waiting. Pathos is building a next-generation biotech with AI at the core. Not as a feature, but as the operating system for how medicines get developed. Backed by NEA.
- Company website: https://pathos.com/
- Type: Startups
- Level: Principal and up
- Location: New York, NY
- Work setup: On-site
- Pay: $210K to $250K base salary per year (USD)
- Posted: 2026-08-10
- Apply by: 2026-10-08
- Apply: https://ats.rippling.com/pathos/jobs/b3442f8f-03f8-4fc7-8f1e-324e88d50e13
- Page: https://www.1752.vc/careers/jobs/pathos-director-cmc-small-molecule-chemistry/

## About the role

We are seeking a Director, CMC – Small Molecule Chemistry to lead the chemistry, manufacturing, and controls strategy for our small-molecule oncology programs. This individual will own drug substance and drug product development — from early clinical supply through late-stage development — ensuring phase-appropriate quality, robust processes, and regulatory-ready documentation. This is a foundational hire on the Pathos CMC/Technical Operations team.

## What they're looking for

- Expert in Synthetic, Organic or Medicinal Chemistry of Oncology Compounds and comfortable building phase-appropriate end-to-end CMC strategy
- Define and execute the end-to-end small-molecule CMC strategy for one or more oncology programs, spanning drug substance (API) and drug product
- Serve as the CMC program lead and single point of accountability, representing CMC on cross-functional program teams alongside Research, Clinical, Regulatory, and Quality
- Translate program goals and timelines into phase-appropriate development plans, budgets, and risk-mitigation strategies
- Direct route scouting, synthetic route selection, and process development for APIs, applying deep synthetic and organic chemistry expertise to deliver scalable, cost-effective, and controllable processes
- Oversee drug product formulation and process development, including solid oral and other dosage forms appropriate to oncology indications

Tags: Clinical